Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Health Claims Petitions Cite Favorable Risk/Benefit Ratio - GU Prof

This article was originally published in The Tan Sheet

Executive Summary

Pending health claims petitions for dietary supplements containing vitamin E, saw palmetto, pysllium, and folic acid/vitamins B6 and B12 are based on "such a favorable risk/benefits ratio that the public should be given proper information concerning the potential benefits of these nutraceuticals," Harry Preuss, MD, Georgetown University Medical Center, maintained at a May 25 press conference on Capitol Hill.

You may also be interested in...



FDA Supplement Health Claim Actions Draw Congressional Criticism

FDA's recent actions regarding dietary supplement health claims are "cause for concern" and "sacrifice First Amendment rights for administrative convenience," Rep. Peter DeFazio (D-Ore.) states in a Jan. 12 letter to Commissioner Jane Henney, MD.

FDA Supplement Health Claim Actions Draw Congressional Criticism

FDA's recent actions regarding dietary supplement health claims are "cause for concern" and "sacrifice First Amendment rights for administrative convenience," Rep. Peter DeFazio (D-Ore.) states in a Jan. 12 letter to Commissioner Jane Henney, MD.

FDA Supplement Health Claim Actions Draw Congressional Criticism

FDA's recent actions regarding dietary supplement health claims are "cause for concern" and "sacrifice First Amendment rights for administrative convenience," Rep. Peter DeFazio (D-Ore.) states in a Jan. 12 letter to Commissioner Jane Henney, MD.

Related Content

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel